Works matching IS 15525260 AND DT 2022 AND VI 18 AND IP 10
Results: 231
Issue Information.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.12902
- Publication type:
- Article
Relationship between beta‐amyloid (Ab) plaque reduction and clinical benefit: the rationale for aducanumab approval.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.070011
- By:
- Publication type:
- Article
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069997
- By:
- Publication type:
- Article
Gut microbiome alterations in Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069987
- By:
- Publication type:
- Article
The case for low‐level BACE1 inhibition for the prevention of AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069737
- By:
- Publication type:
- Article
API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069724
- By:
- Publication type:
- Article
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069715
- By:
- Publication type:
- Article
Neuropathology of a patient with AD treated with low doses of verubecestat.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069556
- By:
- Publication type:
- Article
BACE inhibitor treatment at different stages of amyloid deposition.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069553
- By:
- Publication type:
- Article
ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer's Treatment and Care.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069542
- By:
- Publication type:
- Article
Multitarget evaluation of molecules from marine animals against Alzheimer's disease, related to gamma‐ and beta‐secretases and cathepsin B protein targets.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069448
- By:
- Publication type:
- Article
Age‐related changes in clinically relevant biomarkers in a Beagle model of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069443
- By:
- Publication type:
- Article
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069438
- By:
- Publication type:
- Article
Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer's Disease (EAD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069429
- By:
- Publication type:
- Article
ENVISION: A phase 3b/4 randomized, double‐blind, placebo‐controlled, parallel‐group study to verify the clinical benefit of aducanumab in participants with early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069428
- By:
- Publication type:
- Article
Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069402
- By:
- Publication type:
- Article
ENVISION: Increasing diversity of a large phase 3b/4 confirmatory trial of aducanumab to better understand the efficacy and safety among historically underrepresented participants of Alzheimer's disease research and clinical trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069396
- By:
- Publication type:
- Article
Novel HDAC11 Inhibitors for Alzheimer's Disease Treatment in Preclinical Models.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069366
- By:
- Publication type:
- Article
Sovateltide (IRL‐1620) prevents oxidative damage, mitochondrial dysfunction, and memory loss in a transgenic mouse model of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069330
- By:
- Publication type:
- Article
Brain‐targeted N‐Acetyl Cysteine‐loaded nanoparticle for AD treatment.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069329
- By:
- Publication type:
- Article
Preclinical development of a small molecule inhibitor of tau self‐association for Alzheimer's disease and related dementias.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069317
- By:
- Publication type:
- Article
VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Dose Selection and Interim Safety Results.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069290
- By:
- Publication type:
- Article
Treating Alzheimer's Disease via Donepezil Hydrochloride Loaded Nanoparticles: A Novel Approach for Brain Drug Delivery.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069264
- By:
- Publication type:
- Article
Ex vivo target engagement of the Abeta oligomer disassembling compound RD2 in patient derived brain homogenates.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069258
- By:
- Publication type:
- Article
Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk‐Receptors.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069254
- By:
- Publication type:
- Article
A randomized, placebo‐controlled, double‐blind, Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI‐002 in early AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069253
- By:
- Publication type:
- Article
Impact of Decentralized Clinical Trial Methodologies on Alzheimer's research.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069238
- By:
- Publication type:
- Article
Neuropathological autopsy findings in an individual with Alzheimer's disease who received long‐term treatment with lecanemab (BAN2401).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069220
- By:
- Publication type:
- Article
Naturally Derived Rho‐kinase 2 Inhibitors Acting as Mitophagy Inducer: A Novel Therapeutic Approach for Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069207
- By:
- Publication type:
- Article
Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069198
- By:
- Publication type:
- Article
Investigating Distinct Alpha Synuclein Oligomer‐Mediated Cellular Toxicity.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069175
- By:
- Publication type:
- Article
A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA‐831 in Subjects with Early Onset of Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069165
- By:
- Publication type:
- Article
Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer's Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069141
- By:
- Publication type:
- Article
Apigenin restores memory function in stressed mice.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069135
- By:
- Publication type:
- Article
An M1/sigma‐1 receptor agonist prevents cognitive deficits, reduces amyloid plaques and neuroinflammation in a transgenic rat model of Alzheimer's amyloid pathology.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069100
- By:
- Publication type:
- Article
Effect of calcineurin inhibitors on cognition in a canine model of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069099
- By:
- Publication type:
- Article
Age‐dependent effects of the p75 neurotrophin receptor modulator LM11A‐31 on Alzheimer's disease biomarkers in a 26‐week safety and exploratory endpoint trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069079
- By:
- Publication type:
- Article
An oligomer‐directed Aβ antibody decreases synaptotoxic oligomeric Aβ in brain and improves behavioral abnormality in humanized APP knock‐in mice.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069066
- By:
- Publication type:
- Article
Exploring Combination Therapies in AD: Additive Effects of the QPCT Inhibitor Varoglutamstat and Aducanumab on Aβ Pathology and Biomarkers In Vivo.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069050
- By:
- Publication type:
- Article
Association of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors with time to dementia: a population‐based cohort study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069035
- By:
- Publication type:
- Article
Bioequivalence and safety comparison of once‐weekly donepezil transdermal system with oral donepezil: results of a phase 1 pharmacokinetic study in healthy volunteers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068981
- By:
- Publication type:
- Article
Update on the TOGETHER study: a patient‐ and investigator‐blind, randomized, placebo‐controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal‐to‐mild Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068973
- By:
- Publication type:
- Article
Inhibiting tyrosine kinase c‐KIT as a therapeutic strategy for Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068944
- By:
- Publication type:
- Article
Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Motor Function in Parkinson's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068871
- By:
- Publication type:
- Article
Translational Inhibition of Multiple Neurotoxic Proteins Leads to Improved Cognition in Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068865
- By:
- Publication type:
- Article
Scaffold morphing and in silico studies of potential BACE1 (β‐secretase) inhibitors: A hope for newer dawn in anti‐Alzheimer therapeutics.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068799
- By:
- Publication type:
- Article
A Target Enablement Package for the Inhibition of SHIP1 as a Therapeutic Strategy for the Treatment of Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068781
- By:
- Publication type:
- Article
Treatment of Alzheimer's disease by modulation of microglial neuroinflammation by nasal anti‐CD3 mAb.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068761
- By:
- Publication type:
- Article
Improving Vascular Functions by Bioreactive Nanoparticles for Treatment of Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068708
- By:
- Publication type:
- Article
Chimeric Phagocytic Receptors (CPR) to target Alzheimer's disease pathology.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068704
- By:
- Publication type:
- Article